Quest Licenses Diadem AlzoSure® Predict Alzheimer's Disease Prognostic Technology

 Quest to Develop and Market a Lab-developed Test Based on the IP of AlzoSure Predict® in the United States, Extending its Industry-leading Portfolio of Alzheimer's Disease Blood Tests—

—Validating Clinical Data Suggests that AlzoSure® Predict's Blood-Based Technology Can Help Identify Whether or Not Individuals Will Progress to Alzheimer's Disease Up to 6 Years Before Diagnosis—

https://www.prnewswire.com/news-releases/diadem-spa-announces-exclusive-us-licensing-agreement-with-quest-diagnostics-for-its-alzosure-predict-alzheimers-disease-prognostic-technology-301966759.html